# Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

> **NCT01492920** · PHASE3 · WITHDRAWN · sponsor: **Gynecologic Oncology Group**

## Conditions studied

- Fatigue
- Malignant Ovarian Mixed Epithelial Tumor
- Neuropathy
- Neurotoxicity Syndrome
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Pain
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **DIETARY_SUPPLEMENT:** Acetyl-L-Carnitine Hydrochloride
- **OTHER:** Placebo
- **OTHER:** Questionnaire Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT01492920
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-04
- **Primary completion:** 2015-05
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn
- **Last updated:** 2014-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01492920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01492920, "Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01492920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*